大阳城手机app

basedondatafrom320healthyadultsinPhase1and2trials. Thecandidatetriggeredrobustantibodyresponsesininoculatedpeople,butitremainedunknownifthatwassufficienttopreventCOVID-19infection,researchersdevelopingthevaccinesaidinthepaper. Sinopharm'schairmantoldmedialastmonththatapotentialvaccinecouldbereadybytheendofthisyearwithPhase3testingexpectedtobecompletedinaboutthreemonths. Thenovelcoronavirus,whichhaskilledmorethan750,000peopleglobally,haspromptedaracetodevelopavaccine.Morethan150candidatevaccinesarebeingdevelopedandtestedaroundtheworld. Russiabecamethefirstcountrytograntregulatoryapprovaltoavaccineafterlessthantwomonthsofhumantesting,andashotdevelopedbyChinesefirmCanSinoBilogicshasbeenclearedforuseinthemilitary. Chinaisleadingthedevelopmentofatleasteightvaccinecandidatesindifferentstagesofclinicaltrials. ofresearchneedstobedonebeforewestartclinicaltrialssoastominimizerisks,"ChentoldCCTVinaninterviewonWednesday. Chenandherteamtookastep-wiseapproachinclinicaltrials,startingwiththeminimumdoseandnumberofvolunteers. "Whatyouseeisthatwehaveonevaccineundergoingclinicaltrials,butbehindthatwehaveabout30E

大阳城手机app

candidates,"shesaid. Chen,whohasmademajorachievementsinCOVID-19-relatedbasicresearchanddevelopmentofvaccineandprotectivemedicine,receivedthenationalhonorarytitleof"People'sHero"inthefightagainstCOVID-19onTuesday. Normal 0 7.8磅 0 2 false false false EN-US ZH-CN X-NONE i